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Different  lines  of evidence  support  BDNF  as  a candidate  gene  in  mood  and  anxiety  modulation.  More
recently,  the  Met  allele  of the BDNF  Val66Met  polymorphism  has  been  implicated  in anxiety  in  animal
models  and  anxiety-traits  in humans.  The  aim  of this  study  is  to evaluate  the  a priori  hypothesis  that  the
association  between  anxiety  disorders  and  Val66Met  polymorphism  at the BDNF  gene  would  be  replicated
in  a community  sample  of  children  and  adolescents.  240  subjects  from  a total  sample  of  2457 children
and  adolescents  aged  10–17  years  from  the  public  schools  in  the  catchment  area  of the  primary  care  unit
of  a university  hospital  participated  in this  case-control  study  and  were  assessed  for  psychopathology
using  the K-SADS-PL.  A sample  of  saliva  was  collected  for DNA  analysis  of  Val66Met  polymorphism.  BDNFenetic association studies
olymorphism
enetic
was  the  single  gene  evaluated  in this  sample.  We  found  a signiﬁcant  association  between  carrying  one
copy  of the  Met  allele  and  higher  chance  of  anxiety  disorders  in  children  and  adolescents.  The  association
remained  positive  even  after  the  adjustment  for potential  confounders  (228 subjects;  OR  =  3.53 (CI95%
1.77–7.06;  p  < 0.001)).  Our  results  support  the  a priori  hypothesis  of  an  association  between  anxiety  and
the  polymorphism  Val66Met.  To  our  knowledge,  this  is  the  ﬁrst  study  documenting  a potential  role  of
this  polymorphism  in  a community  sample  of  anxious  children  and  adolescents.nxiety disorders are prevalent in childhood and adolescence and
re associated with impairments in academic, social and family
unctioning, as well as related to the persistence of psychopathol-
gy in adulthood [2]. Family history is one of the best-established
isk factors for anxiety disorders, with heritability estimates rang-
ng from 20 to 40% [12].
Brain  derived neurotrophic factor (BDNF) plays an important
ole in neuronal differentiation during brain development, as well
s in synaptic plasticity and neuronal survival in the adult brain
37]. A common variant of the BDNF gene in humans, consist-
ng of a single nucleotide polymorphism (SNP, rs 6265) in the
rodomain region, which produces a valine-to-methionine sub-
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stitution at codon 66 (Val66Met), has been explored with some
promising results in association to neuropsychiatric disorders [21].
Animal models showed that the Met  allele of the BDNF genotype
is associated with a reduced BDNF secretion and higher anxious
behaviors [5]. If the Met  allele is associated with anxiety disorders
or not is a matter of intense discussion in literature [13,17,35,40].
Some studies have also implicated the Val allele of the BDNF
genotype in vulnerability for anxiety [10,17]. A recent study with
functional neuroimaging in adolescents showed that Met-carriers
had greater neural responses for emotional faces, suggesting that
the Met  allele might affect important neural correlates for anxiety
and depression [19].
The  primary objective of this investigation was  to examine the
role of Val66Met polymorphism in anxiety disorders in childhood
and adolescence. Our a priori hypothesis was that the Met  allele of
Open access under the Elsevier OA license.that BDNF genotype would be a risk factor for anxiety disorders in
this group. To our knowledge this is the ﬁrst investigation examin-
ing the impact of Val66Met in a community sample of children and
adolescents evaluated with stringent criteria for anxiety disorders.
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Cases and controls were selected from a larger community
ample of 2457 children and adolescents (10–17 years) that partic-
pated in a cross-sectional anxiety disorder study [32]. All subjects
cases and controls) came from the same community sample in
he south of Brazil. A recent study with 48 ancestry informative
arkers showed that individuals from southern Brazil present an
lmost exclusively European ancestry [33]. Skin color was  assessed
y observation during the clinical interview. Socio-economic sta-
us was evaluated using an ofﬁcial index of the Brazilian Institute
f Geography and Statistics. All parents provided written informed
onsent for participating in the study. This study is in compliance
ith the Declaration of Helsinki and was approved by the Research
nd Ethics Committee of HCPA (07-595).
The K-SADS-PL (Schedule for Affective Disorder and Schizophre-
ia for School-Age Children – Present and Lifetime Version) is a
emi-structured interview based on the DSM-IV criteria that [14]
as administered to the mother/father followed by a direct inter-
iew with all the child/adolescent. Best-estimate diagnoses were
etermined after reviewing generated diagnoses, symptoms and
mpairment level by clinicians with experience in Child Psychia-
ry (total number of interviewers = 6, kappa = 0.93 across anxiety
isorders).
Children diagnosed with social anxiety disorder, generalized
nxiety disorder, separation anxiety disorder or panic disorder –
ccording to the K-SADS-PL – were selected as cases. Subjects with-
ut any anxiety disorder except for speciﬁc phobia were selected
s controls. Individuals with: (1) signiﬁcant organic illness; (2)
istory of bipolar disorder, pervasive developmental disorder or
ny psychotic disorder; (3) history of alcohol or drugs dependence
r abuse; and (4) clinical suspicious of mental retardation were
xcluded from this study. Table 1 outlines the rates of disorders by
roup, comorbid conditions and gender.
Additionally, subjects were evaluated for the anxiety-related
raits harm-avoidance (HA) and behavior inhibition (BI) using
elf-report instruments. HA was assessed with the Cloninger’s Tem-
erament and Character Inventory [6].  This instrument has already
een used in adolescents [20]. HA is described as a heritable ten-
ency to inhibit or stop behaviors in response to signals of aversive
timuli in order to avoid punishment. The Self-Report Scale of
ehavioral Inhibition – Retrospective Version [30] was used to
ssess childhood BI, a temperamental risk factor for panic and pho-
ic anxiety disorders [36].
DNA was extracted from biological samples of saliva using the
NA 2006 Oragene® Kit (Laboratory Protocol for Manual Puriﬁ-
ation of DNA from 4.0 mL  of Oragene® DNA saliva). Genotyping
able 1
escriptive of cases and controls in the total sample.
Variables Study groups 
Controls (n = 97) Cases (n = 131) 
Gender (female) 57 (60.6%) 93 (75%) 
Age  (years) 12.5 (SD = 2.41) 13.0 (SD = 2.3
Skin  color (white) 69 (73.4%) 83 (65.9%) 
Socio-economic status (disadvantage) 52 (65.0%) 61 (58.1%) 
Psychiatric comorbidities
Enuresis 6 (6.2%) 12 (9.2%) 
Attention deﬁcit hyperactivity disorder 24 (24.7%) 29 (22.1%) 
Oppositional deﬁant disorder 17 (17.5%) 16 (12.2%) 
Tics  5 (5.2%) 12 (9.2%) 
Depressive disorder 11 (11.3%) 34 (26.6%) 
Post-traumatic stress disorder 1 (1%) 9 (6.9%) 
Speciﬁc phobia 17 (17.5%) 65 (49.6%) 
BDNF  genotypes
Val/Val 76 (78.4%) 80 (61.1%) 
Val/Met 18 (18.6%) 50 (38.2%) 
ote: There were no Asian or Indian children in the sample. Data are shown for psychiatr
bbreviations:  OR, odds ratio; CI, conﬁdent interval; SMD, standardized mean difference;
old values indicate p < 0.05.etters 502 (2011) 197– 200
was based on the technique described by Ribasés et al. [31]. The
researchers involved in genotyping were blind for the phenotypes,
and identical procedures were used for genotyping all cases and
controls.
Data are presented as mean ± standard deviation, count and
percentage (%). For the analysis, we  excluded the four Met/Met
individuals, considering the small sample size as suggested by Kauf-
man  et al. [15]. Analysis was carried on using anxiety disorders as
a group. Bivariate analysis between cases and controls were made
with Fisher’s Exact test, Pearson’s Chi-square and independent Stu-
dent’s t-test. We  ran a logistic regression model controlling for
confounders using anxiety disorders group as dependent variable.
A linear regression model was used to analyze anxiety-related traits
(HA and BI). All variables with a p-value less than 0.20 plus age, gen-
der and skin color were included in the model. Additional analysis
was run using as a control group only those subjects without any
psychopathology (n = 61).
Tests for deviation from Hardy-Weinberg equilibrium were con-
ducted with the 2 test for goodness of ﬁt. Statistical analysis was
performed using the software SPSS version 14.0 and PEPI v. 4.0 for
DOS. The level of signiﬁcance used was   ˛ = 0.05. Considering a Met
allele frequency of 20%, we  have a power of 84% to detect OR higher
than 2.5. It is important to note that no other polymorphism or gene
was assessed in this sample thus minimizing chances of Error type
I due to multiple testing.
From the 2457 children that accepted to participate in the cross-
sectional study, 240 attended diagnostic evaluation and had their
saliva collected for DNA extraction for this case–control study. Only
unrelated children were included in the analysis (n = 234). Three
cases and three controls were excluded due to mental retarda-
tion. Hence the ﬁnal sample included 131 cases and 97 controls.
From cases of anxiety disorders, 93 (71%) were diagnosed as having
Generalized Anxiety Disorder, 55 (42%) with social anxiety disor-
der, 46 (35.1%) with separation anxiety disorder and 9 (6.9%) with
panic disorder. Seventy-ﬁve (57.3%) had one anxiety disorder only,
41 (31.3%) had two  anxiety disorders and 15 (1.5%) had three or
four anxiety disorders. Family history of anxiety was positive in 57
(67.9%) patients and 27 (32.1%) controls (OR 1.88, CI95% 1.07–3.31,
p = 0.035).
Demographic data, psychiatric comorbidity and genotype com-
parisons between cases and controls are depicted in Table 1. The
genotypic frequencies observed are very similar to other studies in
Caucasian populations [10]. The sample was in Hardy-Weinberg
equilibrium (Val/Val 156, Val/Met 68, Met/Met 4 individuals,
2 = 1.23; df = 1; p = 0.26).
Statistics
Crude OR (CI95%) or SMD  (CI95%) Test statistic p-Value
OR = 1.94 (1.09–3.48) 0.027
6) SMD  = −0.47 (−1.10 to 0.15) t = −1.47 (df = 226) 0.14
OR = 0.69 (0.38–1.25) 0.24
OR = 0.74 (0.41–1.36) 0.364
OR = 1.52 (0.55–4.23) 2 = 0.678 (df = 1) 0.465
OR = 0.86 (0.46–1.60) 2 = 0.212 (df = 1) 0.751
OR = 0.65 (0.31–1.37) 2 = 1.270 (df = 1) 0.341
OR = 1.87 (0.63–5.50) 2 = 1.332 (df = 1) 0.313
OR = 2.82 (1.34–5.92) 2 = 7.992 (df = 1) 0.007
OR = 7.14 (0.88–57.34) 2 = 4.580 (df = 1) 0.047
OR = 4.63 (2.48–8.66) 2 = 24.924 (df = 1) <0.001
1 2 = 9.62 (df = 1)
OR = 2.63 (1.41–4.92) 0.002
ic comorbidity more frequent than 5%.
 2, chi-square; df, degrees of freedom.
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Table 2
Multivarible logistic regression for anxiety disorders diagnoses.
B Wald OR (CI95%) p-Value
Gender 0.215 0.432 1.24 (0.65–2.35) 0.511
Age 0.007 0.012 1.01 (0.88–1.15) 0.913
Skin  color −0.481 2.244 0.62 (0.33–1.16) 0.134
Val/Met genotype 1.264 12.856 3.54 (1.77–7.06) <0.001
Lifetime depression 1.072 5.400 2.92 (1.18–7.21) 0.020
Lifetime PTSD 1.628 2.076 5.09 (0.55–46.62) 0.150
Lifetime conduct −1.970 2.793 0.139 (0.01–1.40) 0.095
15.64
A
B
a
c
(
e
c
b
(
s
p
i
c
f
a
c
1
(
p
a
m
r
[
t
g
F
f
i
t
b
s
a
p
p
i
d
a
s
e
a
t
r
t
a
o
t
n
b
s
eLifetime speciﬁc phobia 1.357 
bbreviations: PTSD, posttraumatic stress disorder; OR, odds ratio.
old values indicate p < 0.05.
Logistic regression shows that carrying one copy of the Met
llele confers increased chance of having an anxiety disorder during
hildhood and adolescence, OR = 3.53 (CI95% 1.77–7.06; p < 0.001)
Table 2). Secondary analysis considering as the control group
xclusively subjects with no major psychiatric disorder (n = 61)
onﬁrms the difference regarding carrying the Met  allele described
etween anxious patients and non-anxious controls, OR = 3.73
B = 1.32, Wald = 9.76, CI95% 1.63–8.54; p = 0.002; logistic regres-
ion controlled for gender, age, skin color and presence of speciﬁc
hobia). Additionally, we run an analysis including the Met/Met
ndividuals in a dominant model and we still have a positive asso-
iation (cases 51/80 vs. controls 21/76, Fisher’s test, p = 0.0062).
Out of the ﬁnal sample of 228 subjects, 102 were evaluated
or harm-avoidance (HA) and 104 for behavior inhibition (BI). No
nxiety-related traits measures were associated with caring one
opy of Met  allele (mean (SD) for HA Val/Val 16.68 (6.20) vs. Val/Met
7.51 (6.38), p = 0.521; for BI Val/Val 1.93 (0.32) vs. Val/Met 1.93
0.31), p = 0.961).
In our study, we observed that Val/Met genotype was an inde-
endent risk factor for anxiety disorders during childhood and
dolescence. Our results are in agreement with ﬁndings from ani-
al  models [5] and association studies in adulthood that have
eported an association between BDNF and anxiety modulation
9,11,25]. Taken together all these results support the hypothesis
hat BDNF has neurobiological features that makes it a candidate
ene in regulation of anxiety.
At least two possible explanations might account for our results.
irst, BDNF may  be associated with anxiety by interfering in
ear processing orchestrated by mesial temporal lobe structures,
ncluding amygdala and hippocampus. Several evidences suggest
hat hippocampus and amygdala play a major role in the cere-
ral pathways linked to anxiety [1]. According with previous
tudies [3,26,28], individuals heterozygous for the 66Met BDNF
llele have smaller hippocampus volume and worse hippocam-
al dependent memory functions. Second, it is possible that BDNF
olymorphism interfere in serotonin-mediated pathways lead-
ng to anxiety. Decreased BDNF expression has been described in
epressed adolescents exposed to adverse events [4] – and there is
 known relation between traumatic events, anxiety and depres-
ion, with some theoretical common causal pathways. Kaufman
t al. [15] showed an interaction between the BDNF genotype (Met
llele), the gene of the serotonin transporter and maltreatment his-
ory in predicting depression in a sample of children, which was not
eplicated by recent studies [27]. Moreover, chronic antidepressant
reatment with selective serotonin reuptake inhibitors (which are
lso effective in the treatment of anxiety) increases the expression
f BDNF and may  enhance its localization at synaptic level [4].
In our study we found an association between Val/Met geno-
ype and between the dominant model and anxiety disorders, but
ot with anxiety-related traits (harm-avoidance and behavior inhi-
ition) in children and adolescents as it was expected. It can be
uggested that the association between the Met  allele and anxi-
ty is dependent on the presence of symptoms severe enough to9 3.88 (1.98–7.61) <0.001
cause impairment and to reach the diagnostic status. On the other
hand, we  could have not found an association between anxiety
traits and the Val/Met genotype because these traits, differently
from the diagnostic evaluation, were assessed by self-report instru-
ments that could not be completely understood by our subjects. It
is also possible that we  did not have power to detect an association
due to the smaller sample size included in the BI and HA measures.
We analyzed anxiety disorders as a group based on the sig-
niﬁcant comorbidity and overlap between anxiety diagnosis in
children and adolescents [16,29].  Considering the diathesis-stress
theory, anxiety may  be expressed according to stressors during the
life course [22,39]. The analysis considering anxiety as a group is
in agreement to previous studies that have shown that the heri-
tability of anxiety is not disorder speciﬁc [36]. Most studies have
shown moderate convergence between children’s self-report mea-
sures and anxiety diagnoses but demonstrated poorer agreement
at the level of speciﬁc anxiety disorders [34]. Moreover random-
ized clinical trials for anxiety disorders in childhood also evaluate
anxiety disorder as a group [38]. This approach, even not consid-
ering the validity of different diagnosis of anxiety disorders poor,
takes into account a common etiology and treatment response [18].
Besides this, we excluded speciﬁc phobia from the anxiety group
because of its higher frequency and higher rates of remission with-
out treatment [7].  Moreover it has a different factor of heritability
as compared to other anxiety disorders [8].
Yet our study presents some limitations. The moderate sam-
ple size was  due to the origin of the sample – community sample
– subjects were not looking for treatment, and the participation
in the study required a hospital visit both time and cost demand-
ing. Additionally, the risk for biases related to ethnic stratiﬁcation
cannot be excluded and no genomic control was  performed in our
study. Therefore our ﬁndings could have been biased by hidden
genetic heterogeneity that can be present in the Brazilian popula-
tion of European ancestry. This confounding factor was  minimized
through the selection of a community school sample – all the cases
and controls came from exactly the same population and we con-
trolled the analysis for skin color. Another limitation is that we did
not have power to test for gender and gene interaction.
This study is innovative in combining three aspects: (1) a com-
munity sample, (2) a sample comprised by children and adolescents
and (3) a stringent psychiatric evaluation for anxiety disorders.
Previous studies had investigated the effect of BDNF gene in chil-
dren and adolescents, but did not evaluate psychiatric disorder.
One evaluated a sample with “anxious depression symptoms” [24]
and the other one characterized adolescents with internalizing dis-
orders [23]. Studying a community sample avoids the potential
selection biases of clinical samples, such as the restriction to more
severe cases of patients in treatment. In our study, we included as
cases subjects that have never been previously diagnosed as hav-
ing anxiety disorders. Our cases included those with less severe
disorder and those whose parents’ hesitate looking for psychiatric
treatment. Consequently, our ﬁndings can represent a broader con-
cept of anxiety disorders, which is not restricted to severe cases.
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esides this, both cases and controls came from the same popula-
ion, with the same epidemiological background.
Studying psychiatric symptoms in children brings the oppor-
unity of evaluating complex behavior early in the development,
ossibly contributing to the understanding of psychopathologi-
al processes. Our ﬁndings from a community sample of children
nd adolescents assessed through out a detailed clinical evaluation
dd new relevant data to the international literature, since genetic
ndings on this polymorphism in childhood are scarce. Our study
einforces the hypothesis that BDNF can be related to the devel-
pment of early onset of anxiety disorders. Additional studies to
onﬁrm our ﬁndings are necessary.
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